News | June 03, 2024
Supriya Lifescience FY24 PAT up 32%
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
